III. International Enzyme and Bioprocess Days / EBDays 2022, Tokat, Turkey, 9 - 11 September 2022, pp.56
AIDS and Covid-19 is an important public health problem. Violacein is very interesting due to its the
various biological activities, but studies on its antiviral activity are quite limited. Objective of this study
is to determine the effectiveness of crude violacein extract of two Jantihonobacterium strain on HIV1-
RT (Human Immunodeficiency Virus-1 Reverse Transcriptase) and SARS-CoV-2 Spike S1: ACE2.
In this study, crude violacein extracts were obtained from two natural violacein producer
Janthinobacterium sp. strain GK and GMG-1. Extract composition determined by Thin Layer
Chromotography. For testing antiviral activity in vitro; HIV-1 RT inhibition test kit and SARS-CoV-2
Spike S1: ACE2 Biotin interaction inhibition test kit were used. For in silico study AutoDock 4.2, MGL
Tools 1.5.6 and, BIOVIA Discovery Studio Visualizer programs were used.
Both crude violacein extracts (0.8-0.1 mg/ml) showed different inhibition activities on HIV-1 RT
(GMG1 100-14.23%, GK 55.98- 39.92%) and SARS-CoV-2 Spike S1: ACE2 biotin (GMG1 46-29%,
GK 31-5%). Results of in silico analysis suggest that ligand violacein and deoxyviolacein bind
strongly to the receptor ACE2, HIV-1 reverse transcriptase, and SARS-CoV-2 spike receptor-binding
The results of presenting silico and in vitro studies of this work support each other. However, there
are differences in the inhibition effects of GMG-1 and GK extracts. It is thought that this situation is
due to the difference in chemical composition of the extracts.
All in vitro analysis results indicate that the inhibitory activity of violacein and its derivatives increased
in a concentration-dependent manner.